Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALGSNASDAQ:CGENNASDAQ:SLSNASDAQ:TARA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALGSAligos Therapeutics$6.03+8.1%$9.01$3.76▼$46.80$36.87M2.72189,476 shs124,581 shsCGENCompugen$1.52-5.0%$1.52$1.13▼$2.66$135.64M3.19390,523 shs129,244 shsSLSSELLAS Life Sciences Group$1.62+4.5%$1.20$0.77▼$1.84$153.17M2.531.35 million shs2.47 million shsTARAProtara Therapeutics$3.46-1.1%$4.01$1.60▼$10.48$127.21M1.6783,858 shs446,121 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALGSAligos Therapeutics+6.29%+4.10%-32.36%-76.50%-70.82%CGENCompugen+14.29%+11.11%+9.59%-31.91%-17.10%SLSSELLAS Life Sciences Group+8.39%+18.32%+43.52%+16.54%+25.00%TARAProtara Therapeutics+2.94%-16.67%-17.84%-22.22%+17.45%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALGSAligos Therapeutics3.8907 of 5 stars3.51.00.04.82.71.70.6CGENCompugen2.0587 of 5 stars3.54.00.00.02.70.00.0SLSSELLAS Life Sciences Group0.8088 of 5 stars0.04.00.00.02.70.00.6TARAProtara Therapeutics2.2488 of 5 stars3.52.00.00.02.51.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALGSAligos Therapeutics 3.00Buy$70.001,060.86% UpsideCGENCompugen 3.00Buy$4.00163.16% UpsideSLSSELLAS Life Sciences Group 0.00N/AN/AN/ATARAProtara Therapeutics 3.00Buy$20.40489.60% UpsideCurrent Analyst Ratings BreakdownLatest ALGS, TARA, CGEN, and SLS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/28/2025TARAProtara TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.00 ➝ $23.004/16/2025TARAProtara TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$12.003/31/2025ALGSAligos TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$70.00 ➝ $70.003/14/2025TARAProtara TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight3/11/2025ALGSAligos TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$75.00 ➝ $70.003/11/2025TARAProtara TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$22.003/6/2025TARAProtara TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.00 ➝ $23.00(Data available from 5/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALGSAligos Therapeutics$3.95M9.35N/AN/A$30.65 per share0.20CGENCompugen$27.86M4.87N/AN/A$0.73 per share2.08SLSSELLAS Life Sciences Group$1M153.17N/AN/A($0.25) per share-6.48TARAProtara TherapeuticsN/AN/AN/AN/A$6.01 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALGSAligos Therapeutics-$87.68M-$20.90N/AN/AN/A-1,283.19%-114.34%-64.58%5/6/2025 (Estimated)CGENCompugen-$18.75M-$0.1676.00N/AN/A2.67%2.62%1.36%5/19/2025 (Estimated)SLSSELLAS Life Sciences Group-$37.34M-$0.52N/AN/AN/AN/A-629.46%-178.65%5/13/2025 (Estimated)TARAProtara Therapeutics-$40.42M-$2.40N/AN/AN/AN/A-55.96%-49.06%5/1/2025 (Estimated)Latest ALGS, TARA, CGEN, and SLS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/19/2025Q1 2025CGENCompugen-$0.06N/AN/AN/A$3.70 millionN/A5/13/2025Q1 2025SLSSELLAS Life Sciences Group-$0.1067N/AN/AN/AN/AN/A5/6/2025Q1 2025ALGSAligos Therapeutics-$2.80N/AN/AN/A$0.33 millionN/A5/1/2025Q1 2025TARAProtara Therapeutics-$0.47N/AN/AN/AN/AN/A3/20/2025Q4 2024SLSSELLAS Life Sciences Group-$0.1067-$0.08+$0.0267-$0.08N/AN/A3/12/2025Q4 2024TARAProtara Therapeutics-$0.57-$0.48+$0.09-$0.48N/AN/A3/10/2025Q4 2024ALGSAligos Therapeutics-$2.63-$13.08-$10.45-$13.08$0.43 million$0.63 million3/4/2025Q4 2024CGENCompugen$0.07-$0.07-$0.14-$0.07$17.47 million$1.47 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALGSAligos TherapeuticsN/AN/AN/AN/AN/ACGENCompugenN/AN/AN/AN/AN/ASLSSELLAS Life Sciences GroupN/AN/AN/AN/AN/ATARAProtara TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALGSAligos TherapeuticsN/A3.813.81CGENCompugenN/A4.144.14SLSSELLAS Life Sciences GroupN/A2.262.26TARAProtara TherapeuticsN/A9.859.85Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALGSAligos Therapeutics60.43%CGENCompugen12.22%SLSSELLAS Life Sciences Group17.38%TARAProtara Therapeutics38.13%Insider OwnershipCompanyInsider OwnershipALGSAligos Therapeutics8.75%CGENCompugen9.50%SLSSELLAS Life Sciences Group1.20%TARAProtara Therapeutics12.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALGSAligos Therapeutics906.11 million3.27 millionNo DataCGENCompugen7089.24 million80.76 millionOptionableSLSSELLAS Life Sciences Group1094.55 million69.54 millionNot OptionableTARAProtara Therapeutics3036.77 million18.05 millionOptionableALGS, TARA, CGEN, and SLS HeadlinesRecent News About These CompaniesProtara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 1 at 4:09 PM | globenewswire.comHC Wainwright Reiterates Buy Rating for Protara Therapeutics (NASDAQ:TARA)April 30 at 8:34 AM | marketbeat.comAdage Capital Partners GP L.L.C. Buys Shares of 2,250,000 Protara Therapeutics, Inc. (NASDAQ:TARA)April 30 at 5:30 AM | marketbeat.comProtara Therapeutics (TARA) Projected to Post Earnings on ThursdayApril 29 at 3:35 AM | americanbankingnews.comProtara Therapeutics stock drops following interim trial resultsApril 29 at 1:43 AM | investing.comProtara Therapeutics stock drops following interim trial resultsApril 29 at 1:43 AM | investing.comWhy Protara Therapeutics, Inc.’s (TARA) Stock Is Down 18.87%April 29 at 1:43 AM | aaii.comWhy Protara Therapeutics, Inc.’s (TARA) Stock Is Down 18.87%April 29 at 1:43 AM | aaii.comAs J&J aims to 'fundamentally change' how bladder cancer type is treated, ImmunityBio plays defenseApril 28 at 9:19 AM | fiercepharma.comProtara Therapeutics Reports Promising Phase 2 Results for TARA-002 in Non-Muscle Invasive Bladder CancerApril 26, 2025 | quiverquant.comProtara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBCApril 26, 2025 | globenewswire.comProtara Therapeutics (TARA) to Release Quarterly Earnings on ThursdayApril 26, 2025 | marketbeat.comProtara Therapeutics to Host Conference Call on Phase 2 ADVANCED-2 Trial Data for TARA-002 in Non-Muscle Invasive Bladder CancerApril 23, 2025 | quiverquant.comProtara Therapeutics to Host Conference Call and Webcast to Review Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Monday, April 28, 2025April 23, 2025 | globenewswire.comWalleye Capital LLC Takes $1.17 Million Position in Protara Therapeutics, Inc. (NASDAQ:TARA)April 22, 2025 | marketbeat.comChutes & Ladders—AIRNA appoints Elevidys architect as CMOApril 18, 2025 | fiercebiotech.comProtara Therapeutics, Inc. (NASDAQ:TARA) Given Average Recommendation of "Buy" by AnalystsApril 18, 2025 | marketbeat.comProtara Therapeutics (NASDAQ:TARA) Now Covered by Analysts at ScotiabankApril 18, 2025 | marketbeat.comProtara Therapeutics appoints Leonardo Viana Nicacio as chief medical officerApril 17, 2025 | markets.businessinsider.comProtara Therapeutics initiated with an Outperform at ScotiabankApril 17, 2025 | markets.businessinsider.comScotiabank Initiates Coverage of Protara Therapeutics (TARA) with Sector Outperform RecommendationApril 17, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Signs of a more buyer-friendly housing market emerge for the spring homebuying seasonBy The Associated Press | April 6, 2025View Signs of a more buyer-friendly housing market emerge for the spring homebuying season5 Highest-Rated Dividend Stocks According to MarketBeatBy Thomas Hughes | April 10, 2025View 5 Highest-Rated Dividend Stocks According to MarketBeat3 Momentum Stocks That Could Soar Post-Market VolatilityBy Nathan Reiff | April 21, 2025View 3 Momentum Stocks That Could Soar Post-Market VolatilityALGS, TARA, CGEN, and SLS Company DescriptionsAligos Therapeutics NASDAQ:ALGS$6.03 +0.45 (+8.06%) Closing price 04:00 PM EasternExtended Trading$6.13 +0.10 (+1.72%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.Compugen NASDAQ:CGEN$1.52 -0.08 (-5.00%) Closing price 04:00 PM EasternExtended Trading$1.58 +0.06 (+4.28%) As of 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.SELLAS Life Sciences Group NASDAQ:SLS$1.62 +0.07 (+4.52%) Closing price 04:00 PM EasternExtended Trading$1.62 -0.01 (-0.31%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.Protara Therapeutics NASDAQ:TARA$3.46 -0.04 (-1.14%) Closing price 04:00 PM EasternExtended Trading$3.50 +0.04 (+1.16%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Crushes Earnings, What’s Next for MSFT Stock? McDonald’s Insiders Sell Shares! Investors Should Do the Opposite Qualcomm's Earnings: 2 Reasons to Buy, 1 to Stay Away Broadcom: Buy, Hold, Sell? AI & Acquistions Paint Strong Picture Hershey Hits the Sweet Spot for Defensive Investors A Bull Case for Adobe Stock Remains Today AMD Stock Signals Strong Buy Ahead of Earnings BigBear.ai: A Short-Squeeze Is Possible, a Sharp Drop Is Likely Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
